[1]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版).中华内分泌代谢杂志,2021,37(4):311-398.
[2] World Health Organization. Use of glycated haemoglobin(HbA1c)in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation,Diabetes Res. Clin. Pract,2011,93(3):299-309.
[3]中国1型糖尿病诊治指南制定委员会.中国1型糖尿病诊治指南.北京:人民卫生出版社,2013.
[4] HU C,JIA W P. Diabetes in China:epidemiology andgenetic risk factors and their clinical utility in personalized medication. Diabetes,2018,67(1):3-11.
[5] VIRK S A,DONAGHUE K C,CHO Y H,et al. Association between HbA1c variability and risk of microvascular complications in adolescents with type 1 diabetes. J Clin Endocrinol Metab,2016,101(9):3257-3263.
[6] ZOUNGAS S,ARIMA H,GERSTEIN H C,et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes:a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol,2017,5(6):431-437.
[7]秦成勇,王荣.内科及药物治疗学.北京:人民卫生出版社,2006:820-823.